# ONL Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onl-therapeutics

- Industry: Biotechnology
- Headquarters: Ann Arbor, US
- Website: www.onltherapeutics.com/
- Total disclosed funding: $117M
- Latest round: Series D (Sep 12, 2024)
- Investors on record: 18

## About

Based in Michigan, US, and founded in 2011 by co-founders Raili Kerppola Ph.D., David Zacks MD, and Jeffrey Jamison Ph.D., ONL Therapeutics, Inc. operates as a provider of retinal therapeutics to clinical researchers and healthcare professionals focusing on vision-threatening retinal diseases. In September 2024, ONL Therapeutics, Inc. raised USD 60 million in Series D funding led by Johnson & Johnson Innovation, with participation from Bios Partners, Novartis Venture Fund, and Visionary Ventures Fund. As of 2024, the company is led by its CEO, David Esposito.

The company provides a wide range of biopharmaceutical products, such as ONL1204 Ophthalmic Solution for treating geographic atrophy and open-angle glaucoma, as well as research and development in retinal neuroprotection. Additionally, the firm also provides services such as clinical trials and safety assessments for its therapeutic candidates.

The company plans to use its proceeds from September 2024 funding to initiate a Phase 2 worldwide investigation to treat geographic atrophy associated with dry age-related macular degeneration to further the development of ONL1204 Ophthalmic Solution.

## Funding rounds

- Series D, Sep 12, 2024, $60M — Novartis Venture Fund, Johnson & Johnson Innovation, Bios Partners, Visionary Venture Fund
- Series C, Mar 7, 2023, $5M — Johnson & Johnson Innovation, Bios Partners, Kaitai Capital, Biosciences Research & Commercialization Center, PSQ Capital, Exsight ventures, Michigan Investment in New Technology Startups, Visionary Venture Fund, Capital Community Angel Investors, Michigan Capital Network, Alpine Visionary Ventures, Mayewell Capital
- Series B, Jan 13, 2022, $20M — Johnson & Johnson Innovation, Bios Partners, Kaitai Capital, Biosciences Research & Commercialization Center, PSQ Capital, Exsight ventures, Michigan Investment in New Technology Startups, Capital Community Angel Investors, Michigan Capital Network
- Series B, Dec 18, 2020, $27M — Johnson & Johnson Innovation, Bios Partners, Grand Angels, Kaitai Capital, Biosciences Research & Commercialization Center, PSQ Capital, Exsight ventures, Capital Community Angel Investors, University of Michigan MINTS
- Series A, May 17, 2017, $4.3M — InvestMichigan! Growth Capital Fund, Biosciences Research & Commercialization Center, Novartis, Michigan Investment in New Technology Startups, Capital Community Angel Investors, Hestia Insight
- Seed, Jun 17, 2014, $0.5M — Capital Community Angel Investors

## Investors

- Capital Community Angel Investors (https://capitalatlas.ai/funds/capital-community-angel-investors) — Seed, Series A, Series B, Series C
- InvestMichigan! Growth Capital Fund — Series A
- Biosciences Research & Commercialization Center (https://capitalatlas.ai/funds/biosciences-research-commercialization-center) — Series A, Series B, Series C
- Novartis — Series A
- Michigan Investment in New Technology Startups (https://capitalatlas.ai/funds/michigan-investment-in-new-technology-startups) — Series A, Series B, Series C
- Hestia Insight (https://capitalatlas.ai/funds/hestia-insight) — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B, Series C, Series D
- Bios Partners (https://capitalatlas.ai/funds/bios-partners) — Series B, Series C, Series D
- Grand Angels — Series B
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series B, Series C
- PSQ Capital — Series B, Series C
- Exsight ventures (https://capitalatlas.ai/funds/exsight-ventures) — Series B, Series C
- University of Michigan MINTS — Series B
- Michigan Capital Network (https://capitalatlas.ai/funds/michigan-capital-network) — Series B, Series C
- Visionary Venture Fund (https://capitalatlas.ai/funds/visionary-venture-fund) — Series C, Series D
- Alpine Visionary Ventures — Series C
- Mayewell Capital (https://capitalatlas.ai/funds/mayewell-capital) — Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series D